Gain Therapeutics (NASDAQ:GANX – Get Free Report) and Scinai Immunotherapeutics (NASDAQ:SCNI – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.
Valuation & Earnings
This table compares Gain Therapeutics and Scinai Immunotherapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Gain Therapeutics | $50,000.00 | 986.26 | -$20.16 million | ($0.50) | -2.26 |
| Scinai Immunotherapeutics | $1.31 million | 0.49 | -$8.31 million | ($95.34) | -0.00 |
Scinai Immunotherapeutics has higher revenue and earnings than Gain Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Gain Therapeutics and Scinai Immunotherapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Gain Therapeutics | N/A | -161.59% | -118.36% |
| Scinai Immunotherapeutics | N/A | N/A | N/A |
Analyst Ratings
This is a summary of recent ratings and recommmendations for Gain Therapeutics and Scinai Immunotherapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Gain Therapeutics | 1 | 0 | 4 | 0 | 2.60 |
| Scinai Immunotherapeutics | 1 | 0 | 0 | 0 | 1.00 |
Gain Therapeutics currently has a consensus target price of $7.67, suggesting a potential upside of 578.47%. Given Gain Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Gain Therapeutics is more favorable than Scinai Immunotherapeutics.
Insider and Institutional Ownership
12.0% of Gain Therapeutics shares are owned by institutional investors. Comparatively, 58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. 4.2% of Gain Therapeutics shares are owned by insiders. Comparatively, 60.9% of Scinai Immunotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Volatility and Risk
Gain Therapeutics has a beta of 0.19, indicating that its stock price is 81% less volatile than the S&P 500. Comparatively, Scinai Immunotherapeutics has a beta of 2.13, indicating that its stock price is 113% more volatile than the S&P 500.
Summary
Scinai Immunotherapeutics beats Gain Therapeutics on 7 of the 12 factors compared between the two stocks.
About Gain Therapeutics
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.
About Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Receive News & Ratings for Gain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gain Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
